Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma

NCT02951819 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.

NCT NCT02951819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02951819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Lead sponsor
Janssen Scientific Affairs, LLC
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2016
Completion date
August 17, 2020
Enrollment
101 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma